JP2007230969A - Ameliorant for metabolic syndrome - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an ameliorant for metabolic syndrome with reduced adverse reaction and safe in daily intake over long period, having ameliorating efficacy on accumulation of visceral fat together with other risk factors, and to provide a prophylactic agent for arteriosclerosis, and to provide pharmaceuticals and foods comprising the same. <P>SOLUTION: The invention relates to the ameliorant for metabolic syndrome and the prophylactic agent for arteriosclerosis comprising a processed product of leaves of Eucommia ulmoides oliver and a processed product of a vegetable having blood sugar reducing action. The invention relates to the pharmaceuticals and foods comprising the same. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a metabolic syndrome-improving agent containing a processed bamboo leaf product. Furthermore, the present invention relates to a composition for oral intake, a pharmaceutical composition, a food composition and the like containing the metabolic syndrome improving agent.

  Increasing cardiovascular disease due to overnutrition and lack of exercise has become a problem not only in the West, but also in Asia. Conventionally, preventive measures for arteriosclerotic diseases including myocardial infarction and cerebral infarction have been focused on measures against hypercholesterolemia, and other risk factors have been individually dealt with. However, on the basis of obesity and lack of exercise in recent years, there are extremely many cases where multiple risk factors are accumulated in one person based on obesity, and the onset of arteriosclerosis is also seen in many cases from such multiple risk factor syndromes. (See Non-Patent Document 1).

  This multiple risk factor syndrome was called by various concepts such as syndrome X, death quartet, insulin resistance syndrome, visceral fat syndrome, etc. Also defined diagnostic criteria for metabolic syndrome. According to the standard, it corresponds to the accumulation of visceral fat (waist circumference is 85 cm or more for men, 90 cm or more for women), and (1) lipids (neutral fat in blood is 150 mg / dL or more or HDL cholesterol is Less than 40 mg / dL), (2) fasting blood glucose (100 mg / dL or more) and (3) blood pressure (systolic blood pressure 130 mmHg or more or diastolic blood pressure 85 mmHg or more) from (1) to (3) to two or more If applicable, a diagnosis of metabolic syndrome is made (see Non-Patent Document 1).

  Drug therapy for metabolic syndrome is not yet well established, and prescriptions for anti-obesity drugs are being investigated. However, mazindol is known as an anti-obesity drug that is approved for medical insurance in Japan, but the drug is accompanied by restrictions on use of BMI 35 or more and an insurance application period of 3 months or less. In addition, when drug treatment is individually performed for each risk factor of metabolic syndrome, there is a concern that the interaction with the drug combination may adversely affect the symptoms.For example, thiazide diuretics used as antihypertensive drugs are insulin sensitive It is known to adversely affect reduced sugar / lipid metabolism (see Non-Patent Documents 2 and 3).

  Eucommia ulmoides oliver is a deciduous woody tree that is classified as a genus of the family Eucommia from the central part of China and has a height of 20 m. Compared with the camellia plant generally called tea, Tochu does not contain caffeine at all and its contents are also different. Tochu Nakaba has been widely used as a drink since the 1980s. Tochu's bark is treated as a medicine and is used in China as an effective Chinese medicine for "high blood pressure, low back pain, joint pain, kidney disease, liver disease, stress, loss of energy, diuresis, forgetfulness".

  Natural foods and herbal medicines generally have advantages such as fewer side effects, and thus their usefulness against lifestyle-related diseases that have been increasing in recent years has attracted attention. Regarding the above-mentioned Tochu, several examples have also been reported in which the lipase inhibitory activity of Tonaka leaf components was examined (see Patent Documents 1 to 5).

JP 2005-289950 A JP 2005-289951 A JP 2003-342185 A JP 2002-179586 A JP 2002-275077 A Obesity / Metabolic Syndrome Medical Guidance, Medical View, 2005, pp. 10-11 Obesity / Metabolic Syndrome Medical Guidance, Medical View, 2005, pp. 205-206 Obesity / Metabolic Syndrome Medical Guidance, Medical View, 2005, 207-209

  The present invention is a metabolic syndrome-improving agent and arteriosclerosis prevention that uses natural materials as raw materials, is safe even when ingested for a long time with few side effects, and has an effect of improving not only visceral fat accumulation but also other risk factors. An object is to provide an agent, a medicament containing the agent, or a food.

As a result of diligent research to solve the above-mentioned problems, the present inventor found a metabolic syndrome-improving effect in a composition containing processed tochu leaves and completed the present invention.
That is, according to one aspect of the present invention, there is provided a metabolic syndrome-improving agent containing a licorice leaf processed product.

  According to another aspect of the present invention, there is provided a metabolic syndrome ameliorating agent comprising a tochu-naka processed product and a plant processed product having a hypoglycemic effect. Here, as the blood glucose lowering action of the processed plant product, for example, an action caused by an α-glucosidase inhibitory action can be mentioned. In addition, as the processed plant product, Salacia, mulberry leaf, banaba leaf, guava leaf, yacon, olive leaf, bitter gourd, rafu hemp, gymnema, western ginseng, ginseng, carrot, mate tea, morohaya, cargo leaf, caiapo, Extracts of the ginseng, red ginseng, hibamata, mugwort, yellow spirit, rahan fruit, horsetail, yam, ganoderma, etc. The processed plant products preferably used in the present invention are a Salacia extract and a mulberry leaf extract. The Salacia extract and the mulberry leaf extract are available for purchase. The Salacia extract is, for example, Salacia extract D (manufactured by Tada Philosophy) and the mulberry leaf extract is, for example, mulberry leaf extract powder (Nippon Powder Pharmaceutical Co., Ltd.). Can be used in the present invention.

  According to a further aspect of the present invention, there is provided an already defined metabolic syndrome improving agent, wherein said plant processed product is selected from indigestible dextrin and mulberry leaf extract. The indigestible dextrin used here is not particularly limited. For example, water-soluble dietary fiber obtained by treating starch derived from plants (eg, corn, potato, etc.) with digestive enzymes (amylase, glucoamylase, etc.) It may be.

  According to another aspect of the present invention, there is provided an already defined metabolic syndrome ameliorating agent, wherein the processed licorice leaf extract is a centrum leaf extract. The tochu-naka extract is not particularly limited, and examples of the extraction solvent used for producing the extract include water, ethanol, methanol, and mixed solvents thereof.

  In one embodiment of this aspect of the present invention, the processed licorice leaf product is obtained by a production method comprising a step of steaming centrum raw leaves; a step of extracting centrum leaves with water; and a step of concentrating the extract. It may be an extract from Tochu Naka leaf water.

  In another embodiment of this aspect of the present invention, the processed licorice leaf product is a step of steaming the centrum leaf; a step of twisting the centrum leaf; a step of drying the centrum leaf; a step of roasting the centrum leaf; It may be an extract from Tochu leaf water obtained by a production method including a step of extracting with water and a step of concentrating the extract.

According to another aspect of the present invention, there is provided a metabolic syndrome improving agent as defined above, wherein the processed product of dried Nakanaka leaf is a dried product of dried Nakanaka leaf.
In another embodiment of this aspect of the present invention, the processed nakanaka leaf product comprises a step of steaming cocoon leaf, a step of twisting 杜 naka leaf, a step of drying nakanaka leaf, and a step of pulverizing 杜 naka leaf It may be a dried pulverized product of Nakatsuba obtained by the method.

  In another embodiment of this aspect of the present invention, the processed licorice leaf is a step of steaming a centrum leaf; a step of twisting the centrum leaf; a step of drying the centrum leaf; a step of roasting the centrum leaf; It may be a dried crushed product of Tochu leaf obtained by a production method including a step of pulverizing leaves.

  In another embodiment of this aspect of the present invention, the processed licorice leaf is processed by steaming the centrum leaf, drying the cucumber leaf while stirring and / or under pressure; It may be a dried pulverized pulverized product of nakanaka leaf obtained by a production method including a step of drying nakanaka leaf.

  In yet another embodiment of this aspect of the present invention, the processed product of nakanaka leaf is a step of steaming the cocoon leaf, a step of drying the nakanaka leaf with stirring and / or pressure, and a step of homogenizing moisture in the nakanaka leaf A dried chunaka leaf pulverized product obtained by a production method comprising: a step of drying the chunaka leaf; a step of pulverizing the chunaka leaf; and a step of irradiating the chunaka leaf with far infrared rays. May be.

  In yet another embodiment of this aspect of the present invention, the processed product of nakanaka leaf is a step of steaming the cocoon leaf, a step of drying the nakanaka leaf with stirring and / or pressure, and a step of homogenizing moisture in the nakanaka leaf A step of drying with stirring and / or pressure under pressure; a step of drying the leaf of Nakanaka; a step of grinding the leaf of Nakanaka; and a step of drying the leaf of Nakanaka with irradiation of far-infrared rays to the leaf It may be a dried pulverized crushed material obtained by a production method.

  In the above embodiment, the method for pulverizing the dried rice bran leaves is not particularly limited, and examples of the processing method for the pulverized product used for producing the pulverized product include a rotary pulverizer, a pin mill, a collision type pulverizer, A pulverizer such as a jet mill may be used.

  In still another embodiment of this aspect of the present invention, the processed product of nakanaka leaf is a step of steaming cocoon leaf; a step of drying the nakanaka leaf with stirring and / or pressing; Also provided is a green leaf green powder obtained by a production method comprising the steps of:

  In yet another embodiment of this aspect of the present invention, the processed product of nakanaka leaf is a step of steaming the cocoon leaf, a step of drying the nakanaka leaf with stirring and / or pressure, and a step of homogenizing moisture in the nakanaka leaf A step of drying the nakanaka leaf; a step of pulverizing the nakanaka leaf; a step of drying the nakanaka leaf by irradiating far infrared rays to the nakanaka leaf; The resulting Nakanaka leaf powder may be used.

  In yet another embodiment of this aspect of the present invention, the processed product of nakanaka leaf is a step of steaming the cocoon leaf, a step of drying the nakanaka leaf with stirring and / or pressure, and a step of homogenizing moisture in the nakanaka leaf A step of drying and stirring and / or pressing the Nakanaka leaf; a step of drying the Nakanaka leaf; a step of pulverizing the Nakanaka leaf; a step of drying the Nakanaka leaf by irradiating far infrared rays to the Nakanaka leaf; and It may be a Tochu leaf powder obtained by a production method including a step of making leaves into powder by a jet mill.

In the above aspect of the present invention, the cocoon leaves used in the step of steaming the cocoon leaves may not be cut.
In another embodiment of this aspect of the present invention, a manufacturing method comprising a step of obtaining a water extract from a tochu-nakaba processed product that can be produced by the above-mentioned method or a tochu-nakaba green powder that can be produced by the above-described method It may be an extract extracted from Tochu Nakaba water.

  According to another aspect of the present invention, there is provided a metabolic syndrome improving agent as defined above, wherein the processed product of chunaka leaf is a mixture of chunaka leaf extract and dried chuchu leaf ground material. Here, as the pulverized product of the chuchu leaf extract and the dried chuchu leaf, those already defined can be used.

  In yet another aspect of the present invention, there is provided an already defined metabolic syndrome improving agent containing geniposide acid in terms of daily dose, for example, 75 mg or more, preferably 85 mg or more, more preferably 99 mg or more.

  The metabolic syndrome-improving agent of the present invention can prevent arteriosclerosis and atherosclerotic diseases (eg, ischemic heart diseases such as cerebral infarction, myocardial infarction and angina, aortic aneurysm, aortic dissection, obstructive aneurysm sclerosis) Etc.).

  According to still another aspect of the present invention, there is provided a medicament, pharmaceutical composition, food, food composition or oral intake composition comprising a metabolic syndrome improving agent as defined above. Here, the food is not particularly limited, and may be, for example, a functional food, a health food, a health supplement, a nutritional supplement, an insurance function food, a specific insurance food, or a nutrition function food. In such packages, containers, etc., indications such as “metabolic syndrome improvement effect”, “arteriosclerosis prevention effect” and the like may be displayed.

  In addition to the visceral fat reduction effect, the metabolic syndrome-improving agent according to the present invention is (1) blood neutral fat reduction effect, (2) fasting blood glucose level reduction effect, and (3) Any improvement effect of the blood pressure lowering effect can be obtained. For example, the metabolic syndrome improving agent in the present invention can provide visceral fat reduction effect, blood neutral fat reduction effect, and fasting blood glucose suppression effect. At least one of the effects obtained by the combination of the processed licorice leaf processed product and the processed plant product having a hypoglycemic effect is superior to the case where the processed licorice leaf processed product and the processed plant product having a hypoglycemic activity are administered alone. An effect (synergistic effect) can be obtained.

Specific embodiments of the present invention

Hereinafter, the present invention will be described more specifically.
The processed bamboo leaf product in the present invention can be prepared from raw bamboo leaf leaves or dried leaf leaves. Here, the bamboo shoot leaves mean the bamboo leaves before harvesting and before drying, and may be produced by cultivation or collected from nature. For example, fresh leaves before the fall of the current year can be used, and fresh leaves from April to October, preferably from May to August, more preferably from July to August can be used.

  The steaming process of the above-mentioned salmon Nakasei leaves can be performed by a method usually performed in the technical field using a commercially available steamer or an autoclave. For example, it is possible to heat-treat the green leaves by spreading the green leaves on a net conveyor and passing it through a processing chamber filled with non-pressure steam supplied from a boiler. The steaming temperature is not particularly limited, but may be appropriately selected within the range of 90 to 120 ° C., preferably 95 to 110 ° C., more preferably 100 to 110 ° C., for example, depending on the size of Tochu Nakaba. Further, the steaming time can be appropriately selected in the range of 10 to 240 seconds, preferably 20 to 180 seconds, more preferably 20 to 120 seconds. Moreover, the vapor | steam amount to be used can be suitably selected, for example in the range of 200-70 L / min, Preferably it is 170-100 L / min. The treatment amount of the steamed leaves is not particularly limited depending on the moisture content of the fresh leaves, but is appropriately selected within the range of, for example, 3 to 10 kg / min, preferably 4 to 8 kg / min, more preferably 5 to 7 kg / min. sell. This steaming process makes it easier to keep the ingredients of the cocoon leaves by deactivating the enzyme that changes the color of the nakanaka leaves; and the softening of the nakanaka leaves facilitates the subsequent twisting process. Bring effects such as.

  The twisting step in the present invention can be performed using, for example, a commercially available twisting machine, roughing machine or intermediate hammering machine. For example, as a commercially available twister, Terada Seisakusho Co., Ltd., a twister 60 kg type etc. can be used. By this step, the moisture in the Tochu leaf is uniformly prepared while removing excess moisture, and further, it is easy to extract the components unique to Tochu. Although this process can be performed under heating as necessary, it is preferably performed without heating. The time required for this step is not particularly limited, but may be appropriately selected within a range of, for example, 10 to 80 minutes, preferably 20 to 60 minutes, more preferably 25 to 30 minutes. The treatment amount of the cocoon twisted leaves is not particularly limited, but may be appropriately selected within the range of, for example, 25 to 40 kg, preferably 30 to 35 kg, more preferably 32 to 33 kg depending on the moisture content. The moisture content of the chunaka leaf obtained through this step is, for example, 25 to 40%, preferably 25 to 35%, more preferably 25 to 30% on a dry basis.

  The step of drying the above-mentioned Tochu Nakaba can be performed by, for example, exposing it to the sun. Here, the time for exposure to the sun is not particularly limited, and may be appropriately selected within the range of, for example, 96 to 120 hours, preferably 96 to 114 hours, and more preferably 96 to 102 hours. Further, the drying step can be performed using a commercially available dryer. Although the drying method by a dryer is not specifically limited, For example, Terada Seisakusho make and dryer ND120 type | mold can be performed. Although the temperature of a hot air is not specifically limited here, For example, 70-100 degreeC, Preferably it can select from the range of 85-95 degreeC suitably. The time required for this step is not particularly limited, but may be appropriately selected within the range of 5 to 80 minutes, preferably 10 to 80 minutes, more preferably 20 to 80 minutes. The amount of water in the Tochu leaves obtained through this step is not particularly limited, but is, for example, 5% or less, preferably 3% or less, more preferably 2% or less.

  Although the process of roasting the above-mentioned chunaka leaf is not particularly limited, it can be performed using, for example, a commercially available roaster. Although the roasting method in this process is not particularly limited, for example, it can be carried out by a hot air rotary drying fired machine manufactured by Yokoyama Seisakusho Co., Ltd. The time required for this step is not particularly limited, but may be appropriately selected within the range of 30 to 50 minutes, preferably 30 to 45 minutes, more preferably 35 to 40 minutes. The roasting temperature in this step is not particularly limited, but may be appropriately selected within the range of, for example, 100 to 140 ° C, preferably 120 to 140 ° C, more preferably 130 to 140 ° C. The water content of the chunaka leaf obtained through this step is, for example, 8% or less, preferably 4% or less, more preferably 2% or less on a dry basis.

  In the step of obtaining the water extract of the above-mentioned Nakanaka leaf, for example, 5 to 50 kg, preferably 10 to 30 kg, more preferably 15 to 20 kg of water is used for 1 kg of the Nakanaka leaf processed product. Can do. The extraction temperature can be appropriately selected from the range of, for example, 85 to 98 ° C, preferably 90 to 95 ° C. Although extraction time is not specifically limited, For example, 10-120 minutes, Preferably it is 20-90 minutes, More preferably, it can select from 30-60 minutes suitably.

  Filtration of the extract can be performed using, for example, a 30-200 mesh filter. The filtrate may be allowed to stand for a certain period before concentration. Unnecessary substances can be removed by removing precipitates generated by standing. The time for standing is not particularly limited, but may be appropriately selected from, for example, 1 to 24 hours, preferably 6 to 20 hours, and more preferably 8 to 18 hours. Although the temperature at the time of standing is not specifically limited, For example, 0-35 degreeC, Preferably it is 0-16 degreeC, More preferably, it may be suitably selected from 2-8 degreeC.

  Concentration of the extract obtained as a filtrate is performed by a method usually used in the technical field, and can be performed using, for example, a rotary evaporator. The concentration step is, for example, 20 to 140 mmHg, preferably 30 to 120 mmHg, more preferably 40 to 100 mmHg, and may be selected as appropriate under reduced pressure conditions, for example, 30 to 80 ° C, preferably 35 to 70 ° C, more preferably 40. It can be performed at a temperature that can be appropriately selected from a range of ˜60 ° C. By the said concentration process, it concentrates to 5-8% by volume ratio with the original extract, for example, Preferably it is 5.6-7.5%, More preferably, it is 6-6.6%.

  The obtained concentrate can be used as it is as the extract of the tochu leaf extract of the present invention, but can be further subjected to treatments such as centrifugation and heat sterilization. Centrifugation can be performed by a method commonly performed in the art using a commercially available centrifuge. For example, a rotary centrifuge for the batch type, a multi-chamber centrifuge, a decanter centrifuge, a tubular centrifuge, or the like can be used for the fluid type. Centrifugation conditions are not particularly limited. For example, in the case of a batch-type concentric machine, the rotation speed is 1000 to 3100 rpm, preferably 1500 to 2500 rpm, more preferably 1800 to 2000 rpm; for example 210 to 2010 g, preferably 470 to 1310 g, More preferably, it may be performed under conditions appropriately selected from a processing time of 680 to 840 g; and, for example, a processing time of 10 to 60 minutes, preferably 15 to 40 minutes, more preferably 20 to 30 minutes. When a continuous-pass centrifuge is used, it can be performed under conditions appropriately selected from 100 to 400 mesh, preferably 150 to 350 mesh, more preferably 200 to 300 mesh. The supernatant after centrifugation is collected by water filtration, filtration through diatomaceous earth as a filter aid.

  Heat sterilization is performed by heating to 75-100 degreeC, for example, Preferably it is 80-95 degreeC, More preferably, it is 85-90 degreeC. The treatment time for heat sterilization can be appropriately selected from the range of, for example, 60 to 240 minutes, preferably 90 to 220 minutes, more preferably 120 to 180 minutes.

  The concentration ratio of the resulting nakanaka leaf water extract extract is, for example, 5 to 7.5%, preferably 5.5 to 7%, more preferably 6 to 6.5% by volume with respect to the original extract. For example, 6.5%.

  The geniposidic acid content of the resulting extract of nakanaka leaf water is 6 to 40 mg / g, preferably 15 mg / g to 40 mg / g, more preferably 28 to 37 mg / g, for example 30 mg / g.

  The concentrated extract solution can be dried by a method commonly used in the technical field such as spray drying or freeze drying to obtain a powder of extract of tochu leaf water. The extract powder is obtained, for example, 200 to 600 g, preferably 200 to 400 g, from 1 kg of chunaka leaf after the roasting process and before water extraction. The geniposidic acid content of the resulting extract of the extract of nakanaka leaf water is 40 to 100 mg / g, preferably 50 to 90 mg / g, more preferably 60 to 80 mg / g, for example 77 mg / g. The content of the nakanaka leaf glycoside of the obtained nakanaka leaf water extract powder is 30 to 60 mg / 100 g, preferably 35 to 55 mg / 100 g, more preferably 40 to 50 mg / 100 g, for example, 47 mg / 100 g.

  The tsunaka leaf obtained by the step of drying the above nakanaka leaf can be directly subjected to a step of making a powder by a jet mill, but may be temporarily pulverized before the step. Here, the method of temporary pulverization is not particularly limited, but for example, it can be performed using a commercially available pulverizer. The pulverization method in this step is not particularly limited. For example, the pulverization method may be performed by Coroplex 250Z type manufactured by Hadano Sangyo Co., Ltd. The size of the chunaka leaf obtained through this step is, for example, 150 μm or less, preferably 100 μm or less, more preferably 75 μm or less.

  In the present invention, the step of making Tochu Naka into a powder (for example, a powder having an average particle diameter of 3 to 14 μm) by a jet mill is not particularly limited, but can be performed using, for example, a commercially available jet mill. Here, the compressed air used in the jet mill may be heated, and may be, for example, a temperature appropriately selected from the range of 70 to 150 ° C, preferably 90 to 150 ° C, more preferably 105 to 150 ° C. . When pulverization is performed by heating compressed air, there is an advantage that heat sterilization can be performed in this step, but discoloration after powder processing from Tochu Naka is very slight. Furthermore, the uniformity of the powder particle size is improved. The resulting Tochu leaf powder has an average particle size in the range of 3 to 14 μm, preferably 4 to 8 μm, particularly preferably 4.5 to 6 μm, for example 5 μm. Moreover, the tsunaka leaf powder obtained at this process has a median diameter of 2-14 micrometers, for example, Preferably it is 2-8 micrometers, Most preferably, it is 4-5 micrometers, for example, is 5 micrometers. Moreover, the licorice leaf powder obtained in this step has a mode diameter in the range of, for example, 2 to 32 μm, preferably 2 to 9 μm, particularly preferably 4 to 6 μm, for example 5 μm.

The raw material supply amount to the pulverization chamber in this step is 1 to 12 kg / hour, preferably 1 to 8 kg / hour, more preferably when the input air volume is fixed at 5.5 m ³ / min and the pulverization pressure is fixed at 0.6 Mpa. It may be appropriately selected within the range of 1 to 6 kg / hour. The moisture content of the chunaka leaf obtained through this step is, for example, 6% or less, preferably 4% or less, more preferably 2% or less on a dry basis.

  The term “metabolic syndrome ameliorating agent” used in the present specification is not particularly limited. For example, in addition to the visceral fat reducing effect, (1) blood neutral fat reducing effect, (2) fasting blood glucose It means a drug that is administered to obtain any of the effect of decreasing the value and (3) the blood pressure lowering effect. For example, the metabolic syndrome improving agent in the present invention may have a visceral fat reducing effect, a blood neutral fat reducing effect, and a fasting blood glucose suppressing effect.

  The metabolic syndrome-improving agent and arteriosclerosis-preventing agent of the present invention are not particularly limited, but other agents that can be used for improving metabolic syndrome, such as fat absorption inhibitors, agents for treating or preventing obesity, It can be used together with a prophylactic and therapeutic agent for antilipidemia and a therapeutic or prophylactic agent such as diabetes and hypertension.

  The metabolic syndrome improving agent and arteriosclerosis preventing agent of the present invention can be used as an active ingredient of a pharmaceutical composition. The pharmaceutical composition can be used in various dosage forms such as tablets, capsules, powders, granules, pills, solutions, emulsions, suspensions, solutions, spirits, syrups, for oral administration. For example, it can be a cream, jelly, gel, paste, ointment and the like for topical administration, but is not limited thereto. The pharmaceutical composition may contain various commonly used components, such as one or more pharmaceutically acceptable excipients, disintegrants, diluents, lubricants, flavoring agents, Coloring agents, sweetening agents, flavoring agents, suspending agents, wetting agents, emulsifying agents, dispersing agents, adjuvants, preservatives, buffering agents, binders, stabilizers, coating agents and the like can be included. The pharmaceutical composition of the present invention may be in a sustained or sustained release dosage form.

  The dosage of the metabolic syndrome-improving agent and the arteriosclerosis-preventing agent of the present invention can be appropriately selected depending on the patient's body shape, age, physical condition, degree of disease, elapsed time after onset, etc. The pharmaceutical composition of the present invention Can include a therapeutically effective amount and / or a prophylactically effective amount of a metabolic syndrome ameliorating agent and an arteriosclerosis preventing agent. For example, it is generally used at a dose of 10 to 50000 mg / day / adult, preferably 100 to 5000 mg / day / adult, as the pulverized mash of the present invention or its water extract. Administration of the pharmaceutical composition may be a single dose or multiple doses, and may be used in combination with other drugs such as other metabolic syndrome improving agents and arteriosclerosis preventive agents.

  The food according to the present invention includes a liquid beverage and a solid food. The food can be used as a quasi-drug, other ingredients such as food and drink, food additives and the like. In addition, the composition for oral consumption in the present specification can be used as a functional food as it is, and can be used as a component of a pharmaceutical product, quasi-drug, food and drink, a food additive, and the like. The use enables daily and continuous ingestion of the food or the composition for oral intake having the metabolic syndrome improving effect and the arteriosclerosis preventive agent of the present invention, effective improvement of metabolic syndrome, and arteriosclerosis and Effective prevention of arteriosclerotic disease becomes possible.

  Examples of foods or beverages containing the metabolic syndrome-improving agent and arteriosclerosis preventive agent of the present invention include functional foods having a lipase inhibitory effect or obesity-suppressing effect, health foods, health supplements, nutritional supplements (nutrient drinks, etc.) , Insurance functional food, food for specified insurance, functional nutrition food, general food (juice, confectionery, processed food, etc.). The food or beverage herein includes, as optional additives, inorganic components such as iron and calcium, various vitamins, dietary fibers such as oligosaccharides and chitosan, proteins such as soy extract, lipids such as lecithin, salt Sugars and sugars such as lactose, sweeteners such as aspartame, acesulfame potassium, stevia, saumatine, saccharin, sodium saccharin and the like can be included.

  EXAMPLES Hereinafter, although the preferable Example of this invention is described in detail, this invention is not limited to these Examples.

[Example 1] Preparation of Tochu Nakaba Extract (1) Manufacture of Tochu Nakayo Processed Product for Water Extraction Manufacture of Tochu Nakayo Processed Product for Water Extraction is based on the description in Example 2 of JP-A-8-173110. I went. 5 kg of fresh leaves of Tochu were steamed at 110 ° C. for 90 seconds with a zonal steamer for producing Japanese tea. Fresh leaves were put into the machine from the inlet of the zonal steamer, steam was applied from the upper and lower steam supply devices while moving on the conveyor, and steamed at 110 ° C. for 90 seconds. By spreading the cocoon leaves on the net conveyor and passing them through a treatment chamber filled with non-pressure steam supplied from a boiler, the cocoon leaves can be steamed. For example, Miyamura Tekko Co., Ltd., a feeder, a ground type 1500, a net conveyor, and a banding type 1000 can be used.

  Next, after steaming, the steamed rice leaves were twisted for 30 minutes using a twisting machine, and the twisted material was dried using a dryer at 80 ° C. for 5 hours to a moisture content of 5%. The color of Tochu Nakaha, which was greenish brown after steaming, changed to greenish brown with drying. Then, it was roasted at 110 ° C. for 30 minutes using a fried leaf machine (IR-10SP type: Terada Seisakusho) to obtain 2 kg of a nakanaka leaf processed sample for water extraction.

(2) Preparation of Tochu Nakaba Extract 1 kg of a tochu-nakaba processed product sample for water extraction was put into 15 kg of hot water at 90 ° C. and extracted at 90 ° C. for 30 minutes to obtain 14 kg. Thereafter, the mixture was filtered using a 150 mesh filter, and the filtrate was cooled to 5 ° C. and left overnight. The supernatant was taken out, and the filtrate was concentrated at 50 ° C. under reduced pressure to obtain 1 kg.

  The concentrated solution was processed with a centrifuge KS8000 manufactured by Kubota Corporation, the precipitate was removed by centrifugation at a rotational speed of 1800 rpm, and the resulting supernatant was sterilized by heating (85 ° C., 2 hours). An extract was obtained. The concentrated extract solution was dried by a spray drying method to obtain a powder (300 g) of Tochu leaf extract as a brown powder.

[Example 2] Preparation of chunaka leaf powder (1) Production of dried nakanaka leaf In the production of dried nakanaka leaf, 120 kg of nakanaka leaf was steamed and heat-treated in an indwelling steamer and dried with stirring and under pressure in a leaf cutter. The water in the Nakanaka leaf was homogenized with a twister. Then, it dries with stirring and under pressure with a leaf cutter to make the water in the bamboo leaf uniform. The dried nakanaka leaf thus obtained was dried with a re-dryer to obtain a dried nakanaka leaf. The conditions in each process are shown below:
Banding steamer: steam volume 140L / min, steaming time 80 seconds, steam temperature 100-110 ° C. Leaf cutter: 36 rpm
30 kg of the obtained dried rice bran leaves were pulverized to 1.4 mm to 2.8 mm using UGC-280 type manufactured by Horai Co., Ltd. Next, using a far-infrared roasting machine, a ceramic heater was irradiated with one lamp at each of the upper and lower stages for a passage speed of 45 seconds, and roasted at about 200 ° C. to obtain 26 kg of roasted dried rice bran leaves.

(2) Preparation of Tochu Nakaba Powder 26 kg of the roasted dried Tochu Nakaba obtained in Example 2 (1) was pulverized to 75 μm with Coroplex 250Z, manufactured by Hadano Sangyo Co., Ltd., and pulverized with a jet mill. The pressure was fixed at 0.6 Mpa, and the raw material supply amount was finely pulverized at 4 kg / hour. When pulverizing with this jet mill, 0.98 kg of dried rice bran powder in which compressed air was heated to 150 ° C. was obtained.

[Example 3] Evaluation test of metabolic syndrome-improving action of Tochu Nakaba extract (1) Preparation of test food As test food, powder of Example 1 was contained at 50% by weight or more, and powdered reduced maltose starch syrup (excipient) Amarty MR-100 (made by Towa Kasei Kogyo Co., Ltd.) is 43.3% by weight, sucrose fatty acid ester (Ryoto Sugar Ester S-370F: made by Mitsubishi Chemical Foods) is 5% by weight, fine silicon dioxide (Carplex FPS- 500: DSL Japan Co., Ltd.) 1.7% by weight of uncoated tablets (333 mg per tablet, geniposide acid content of 10 mg) coated with a small amount of surface agent (Lack Glaze 20E: Nippon Shellac Kogyo Co., Ltd.) Tablets were produced.

(2) Test method The test was an open test with an intake period of 4 weeks, with a total of 6 adult men and women as subjects.
During the ingestion period, the subject was ingested daily for 9 tablets (total content of geniposide acid 90 mg) described in Example 3 (1). The subjects were instructed not to change their dietary habits, smoking amount, exercise, and other daily lives except for taking the test meal at regular times every day.

The measurement was performed twice at the start of the test and 4 weeks after ingestion, and blood neutral fat level, fasting blood glucose level, blood pressure, and waist circumference were as follows.
The blood sampling method is to collect about 10 ml (15 ml after the start of the test meal) once before meals (early morning fasting; fasting for 10 hours after dinner the previous day), and then dispense into 4 sample tubes. did.

  For the measurement of blood pressure, systolic blood pressure was measured twice with an automatic sphygmomanometer (HEM-1000 manufactured by OMRON Corporation) in a sitting position after a rest period of at least 5 minutes. However, when the second time was different from the first time in the systolic blood pressure by 10 mmHg or more, the measurement was performed again, and the measurement was performed until it was stabilized within this range. The blood pressure value was defined as an average value of two measurements of the automatic blood pressure monitoring device.

  The waist circumference was measured at the end of the natural exhalation by placing both arms naturally on the side of the body, removing tension on the abdominal wall, and standing at the umbilical position. For the measurement, a measure made of non-stretchable cloth was used.

  All measured values are shown as average values. In addition, a paired t-test was performed for comparison between the intake start date and the fourth week of intake.

(3) Results The results are shown in Table 1. By taking 9 tablets (geniposide acid total content: 90 mg) described in Example 3 (1) as a single day, blood neutral fat and contraction after 4 weeks compared with the start of ingestion The blood pressure and waist circumference tended to decrease.

[Example 4] Evaluation test of metabolic syndrome improving action of Tochu leaf powder (1) Preparation of test food The test meal used the powder of Example 2.

(2) Test method The test method was the same as in Example 3, and the test was conducted with five adult men and women.
The subject was ingested daily for 3 days (geniposide acid content 85 mg) described in Example 4 (1) during the intake period.

(3) Results The results are shown in Table 2. By taking the powder described in Example 4 (1) (geniposide acid content is 85 mg) as one day, blood neutral fat, systolic blood pressure, The waist circumference tended to decrease.

[Example 5] Evaluation test of metabolic syndrome-improving effect of Tochu Nakaba extract, Tochu Naka powder and Mulberry leaf extract (1) Preparation of test food The test food was prepared by the following method. 55.6% by weight or more of the powder of Example 1, and 23.3% by weight or more of the powder of Example 2, and 10% by weight of mulberry leaf extract powder (manufactured by Nippon Powder Chemical Co., Ltd.) After mixing with 4.7% by weight of crystalline cellulose (Theolas FD-301: manufactured by Asahi Kasei Chemicals) as an excipient, kneaded with purified water at 3.5% by weight and ethanol at 35% by weight. The product was dried with a dryer at 45 ° C. for 15 hours to evaporate purified water and alcohol. After granulation, 5.7% by weight of sucrose fatty acid ester (Ryoto Sugar Ester S-370F: manufactured by Mitsubishi Chemical Foods) and 1.8% of fine silicon dioxide (Carplex FPS-500: manufactured by DSL Japan) After mixing as a percentage, yeast wrap (manufactured by Kirin Brewery Co., Ltd.) as a surface agent was 22.2% by weight to the uncoated tablets (300 mg per tablet, content of geniposide acid 11 mg per tablet) obtained by tableting Tablets were produced by coating and drying glycerin (manufactured by Kao) with a mixed solution of 0.36% by weight.

(2) Test method The test method was the same as in Example 3. The measurement data of the subject was extracted based on the set value of the measurement item, and shown as an average value. The set values and the number of subjects are as follows. Blood triglyceride value: subjects with blood triglyceride value of 150 mg / dL or more at the start of ingestion (n = 8), systolic blood pressure, waist circumference and visceral fat cross-sectional area: visceral fat cross-sectional area of 100 square at the start of ingestion Subjects with cm or higher (n = 10), fasting blood glucose level: subjects with fasting blood glucose level of 85 mg / dL or higher at the start of ingestion (n = 8).

During the ingestion period, subjects took 9 tablets (geniposide acid content 99 mg) described in Example 5 (1) as a daily dose.
For visceral fat cross-sectional area, abdominal CT scan imaging was performed, and abdominal fat accumulation was determined from umbilical tomographic images during expiration.

(3) Results Table 3 shows the results. By taking nine tablets of Example 5 (1) (geniposide acid content: 99 mg) as one day, blood neutral fat, systolic blood pressure, hungry after 4 weeks compared with the start of ingestion Blood glucose level, waist circumference and visceral fat cross-sectional area tended to decrease.

  Mulberry leaves have α-glucosidase inhibitory activity and are known as a blood glucose level improving material, but in the literature (Food and Development VOL.37 NO.10, 54-56) The effect is recognized. In addition, there is a description in the literature that 1-deoxynojirimycin known to have α-glucosidase inhibitory activity is contained in 0.1% or more of the dried product in the test product. The per capita intake is 1.8 mg. The amount of mulberry leaves taken as a daily dose in this test food is about 270 mg, and the daily intake of 1-deoxynojirimycin is 0.0837 mg. Therefore, it was clarified that the blood glucose level was improved by using an amount smaller than that of Tochu Naka and the known mulberry leaves.

[Example 6] Evaluation test of metabolic syndrome-improving action of Tochu leaf powder and indigestible dextrin (1) Preparation of test food The test meal was 62.5% by weight of the powder of Example 2 and indigestible dextrin ( A powder in which 37.5% by weight of Fiber Sol 2: Matsutani Chemical Industry Co., Ltd. was mixed was produced (8 g per bag, content of geniposide acid 125 mg).

(2) Test method The subjects were seven adult men and women.
In the test, a comparative test of postprandial blood glucose level was performed on the test food of Example 6 (1) and the indigestible dextrin. The subject fasted from 22:00 on the previous day and measured the initial blood glucose level at 9:00 on the next day. Immediately after ingesting 1 bag of test food of Example 6 (1) or 5 g of indigestible dextrin test meal, the same meal was taken, and blood glucose levels were measured 30 minutes and 120 minutes after meal. In addition, intake other than water was restricted until the end of the test.

  The blood glucose level is measured by collecting blood from a finger capillary using a puncture needle for blood collection (Finetouch: Terumo Corp.) and immediately measuring the blood glucose level using a blood glucose meter (Medisafe Mini GR102: Terumo Corp.). It was measured.

(3) Results Table 4 shows the results. One bag of powder described in Example 6 (1) (geniposide acid content: 125 mg) showed a fasting blood glucose level equivalent to 5 g of indigestible dextrin.

  It is known that indigestible dextrin suppresses glucose absorption caused by hydrolysis of sucrose and maltose without inhibiting disaccharide-degrading enzymes such as sucrase and maltase, and has an effect of suppressing an increase in blood glucose level. In the literature (Journal of Japanese Dietary Fiber Research Institute, Vol. 3, No. 1, 1999, 157-163), the effect is recognized by ingesting 5 g to humans. The indigestible dextrin ingested as a daily dose in this test food was only 3 g, and it was revealed that the blood glucose level was improved by the combined use with Tochu Nakaba.

Claims (17)

  Metabolic syndrome remedy containing Tochu Nakaba processed products.   The metabolic syndrome improving agent according to claim 1, further comprising a processed plant product having a blood glucose lowering effect.   The metabolic syndrome improving agent according to claim 2, wherein the plant processed product is selected from indigestible dextrin and mulberry leaf processed product.   The metabolic syndrome improving agent according to claim 2 or 3, wherein the processed plant product has an α-glucosidase inhibitory action.   The metabolic syndrome improving agent according to any one of claims 2 to 4, wherein the processed plant product is a plant extract.   The metabolic syndrome improving agent according to any one of claims 1 to 5, wherein the processed licorice leaf extract is a licorice leaf extract.   The said Nakanaka leaf processed product is the Nakanaka leaf water extract obtained by the manufacturing method including the process of steaming the Nakanaka green leaf; the process of extracting a Nakanaka leaf with water; and the process of concentrating the said extract. The metabolic syndrome improving agent described in 1.   A process in which the processed Nakanaka leaves are steamed; a process of twisting the Nakanaka leaves; a process of drying the Nakanaka leaves; a process of roasting the Nakanaka leaves; a process of extracting the Nakanaka leaves with water; and the extract The metabolic syndrome-improving agent according to claim 6 or 7, which is an extract of Tochu leaf extract obtained by a production method including a step of concentrating the syrup.   The metabolic syndrome-improving agent according to any one of claims 1 to 5, wherein the processed product of dried nakanaka leaf is a pulverized product of dried nakanaka leaf.   The pulverized product is a pulverized product obtained by a production method including a step of steaming a cocoon leaf, a step of twisting the cocoon leaf, a step of drying the cocoon leaf, and a step of pulverizing the cocoon leaf. The metabolic syndrome improving agent described.   A step in which the pulverized product is steamed in the cocoon leaves; a step in which the cocoon leaves are dried with stirring and / or pressure; a step in which the water in the nakanaka leaves is uniformed; a step in which the nakanaka leaves are dried; The method according to claim 9 or 10, wherein the powder is obtained by a production method including a step of drying the tsuchu leaf by irradiating far-leaved infrared rays on the chunaka leaf; and a step of powdering the chunaka leaf with a jet mill. The metabolic syndrome improving agent described.   The metabolic syndrome-improving agent according to any one of claims 1 to 11, wherein the processed licorice leaf extract is a mixture of a crushed material of licorice leaf extract and dried licorice leaf.   The metabolic syndrome improving agent according to any one of claims 1 to 12, which contains 85 mg or more of geniposide acid in terms of a daily dose.   The metabolic syndrome improving agent according to any one of claims 1 to 13, which is used for prevention of arteriosclerosis.   The pharmaceutical containing the metabolic syndrome improving agent of any one of Claims 1-14.   The foodstuff containing the metabolic syndrome improving agent of any one of Claims 1-14.   The food according to claim 16, which is a functional food, a health food, a health supplement, a nutritional supplement, an insurance function food, a specific insurance food or a nutrition function food.